| Symbol | PLX |
|---|---|
| Name | PROTALIX BIOTHERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 2 UNIVERSITY PLAZA,SUITE 100, HACKENSACK, New Jersey, 07601, United States |
| Telephone | +1 201 - 696-9345 |
| Fax | — |
| — | |
| Website | https://www.protalix.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001006281 |
| Description | Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The companys products also treat diseases like Fabry disease and cystic fibrosis.The companys primary sources of revenues include its sales of taliglucerase alfa in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement. Additional info from NASDAQ: |
Pluxee réalise au T3 une performance conforme aux attentes et confirme ses objectifs financiers
Read morePluxee reports Q3 Fiscal 2026 performance in line with expectations and confirms its financial objectives
Read morePluxee prend connaissance de la requête déposée par la Fiscalía Nacional Económica au Chili
Read morePluxee acknowledges the filing of a claim by the Chilean Competition Authority
Read more(10% Negative) PROTALIX BIOTHERAPEUTICS, INC. (PLX) Reports Q2 2026 Financial Results
Read morePluxee annonce la finalisation d’un programme de rachat d’actions de 100 millions d’euros
Read morePluxee announces the completion of a 100 million euros share buyback program
Read more